Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 8 licensed vaccines, including recently approved 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV-2).

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of multiple products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)

For the prevention of cervical cancers and precancerous lesions caused by human papillomavirus types 16/18.

Haemophilus Influenzae Type b Conjugate Vaccine

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.